Skip to main content
Premium Trial:

Request an Annual Quote

F-Star Therapeutics to Use Inivata's RaDaR Assay in Clinical Studies

NEW YORK – Inivata and F-star Therapeutics on Tuesday announced a collaboration to use Inivata's RaDaR circulating tumor DNA, or ctDNA, liquid biopsy assay in clinical studies of F-star's bispecific antibody drug candidates.

The RaDaR liquid biopsy assay was granted breakthrough therapy designation by the US Food and Drug Administration in March. RaDaR tracks up to 48 tumor-specific variants to detect residual disease following initial cancer treatment. F-star will use the assay to identify and evaluate potential early biomarkers of clinical efficacy in its studies.

"Through the highly sensitive detection of ctDNA with a personalized assay, RaDaR can provide early insights into the efficacy of drug candidates for solid tumors in individual patients and allow for more rapid and efficient clinical trials," Peter Collins, chief business officer of Inivata, said in a statement. "We are excited to be working with F-star to support the clinical development of their highly innovative bispecific antibodies."

F-star has four bispecific antibody candidates in clinical trials, including a dual LAG-3 and PD-L1 inhibitor, a CD137 and OX40 inhibitor, a CD137 and PD-L1 inhibitor, and a STING pathway agonist.

In data presented last year, the Inivata RaDaR assay showed high sensitivity for detecting cancer recurrence and minimal residual disease at various DNA inputs.